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OBJECTIVES: Treatment-resistant depression (TRD)
occurs in 10%–20% of all diagnosed cases of major
depression. There are currently no speciﬁc codes to 
identify TRD in administrative databases. The objectives
of this study were to: (1) apply an algorithm to identify
TRD-likely patients among a population of Saskatchewan
Health (SH) recipients who had a claim with a depression
diagnosis and at least one antidepressant prescription
between January 1, 1993 and December 31, 1995; (2)
determine the prevalence of TRD in this population; and
(3) assess differences in costs and resource utilization for
TRD-likely versus TRD-unlikely patients.
METHODS: A TRD-likelihood algorithm based on anti-
depressant switches, titrations and augmentation therapy
was applied in a SH claims sample of 13,533 pharmaco-
logically treated depressed patients to determine which
were likely to have TRD. Comparisons between the TRD-
likely and TRD-unlikely groups in resource utilization
and annualized costs were made using Wilcoxon tests for
continuous variables and chi-square tests for categorical
variables.
RESULTS: 863 patients (6.4%) were identiﬁed as TRD-
likely. TRD-likely patients had signiﬁcantly higher costs
and resource utilization compared to the TRD-unlikely
patients for all measured outcomes. Median annualized
costs per patient for hospital, physician and prescription
services were CAD$1403 for TRD-likely and CAD$548
for TRD-unlikely (p < .0001). The median number 
of health claims per patient was 51 for TRD-likely 
compared to 27 for TRD-unlikely (p < .0001). TRD-likely
patients had more physician visits (p < .0001) and hospi-
tal admissions (p < .0001) and had a longer median length
of stay (8 days vs. 4 days, p < .0001).
CONCLUSION: Patients who have TRD consume 
signiﬁcantly more medical resources and have higher
medical costs associated with their treatment than non-
TRD patients. Additional research is needed to under-
stand the biological and behavioral differences between
these populations. Successful management of this sub-
population of depressed patients may reduce treatment
costs and resource consumption for depression.
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OBJECTIVES: This study investigates the impact of
Attention-Deﬁcit/Hyperactivity Disorder (“ADHD”) on
the prevalence and costs of accidents. The unique contri-
bution of this research is that it estimates a model that
predicts the probability of having an accident for indi-
viduals with and without ADHD.
METHODS: Administrative claims data from a large
employer (n > 100,000) were analyzed. ADHD patients
were identiﬁed as beneﬁciaries with one or more claims
for ADHD in the study period (1996–98). The ADHD
patient sample was compared to a matched control
sample. In addition to descriptive analysis, multivariate
analysis involving logistic regression was used to estimate
a model of the probability of having an accident.
RESULTS: ADHD patients have a greater incidence of
accidents than their controls (32% v. 20%). However,
given that a patient has an accident, the average number
of accident claims is the same between both groups (3.6
v. 3.5). Accident speciﬁc costs are greater for ADHD
patients than controls ($209 vs. $131) because patients
with this condition are more likely to have accidents.
Among patients with accident claims, ADHD patients
and controls had statistically similar costs. The multi-
variate analysis conﬁrms the utilization patterns found in
the descriptive analysis. The odds of having an accident
for ADHD patients are 1.7 times as great as that for con-
trols after taking account of all the other variables.
CONCLUSIONS: ADHD is a signiﬁcant predictor of
having an accident. However, given that a person has an
accident, ADHD patients generally have a similar number
of accident claims and costs as their controls.
PMH17
ECONOMICS OF PERSISTENCE WITH INITIALLY
PRESCRIBED ANTIPSYCHOTIC IN OLDER
PSYCHOTIC PATIENTS AND IN PATIENTS WITH
BIPOLAR DISORDER
White R1, Simons WR2, Bassi R2
1AstraZeneca, Wilmington, DE, USA; 2Global Health
Economics & Outcomes Research, Inc, Summit, NJ, USA
OBJECTIVE: To evaluate persistency with various
antipsychotic monotherapies and whether improved per-
sistency translates into cost savings.
METHODS: We use longitudinal claims data from 180
MCOs to identify 220 quetiapine patients who were new
to therapy and initiated on monotherapy between
October 1, 1997 and March 31, 1999 and tracked
through June 2000. Matched patients were randomly
selected to populate three comparator groups: haloperi-
dol, risperidone, and olanzapine. Primary endpoint was
the duration on monotherapy. Secondary endpoint was
whether costs decreased with greater duration on
monotherapy. Psychiatric related costs were also aggre-
gated by type of service. Analyses consisted of Cox 
proportional hazard models for time on monotherapy
and linear regressions for cost. Three subset analyses were
performed: patients aged 45 to 64, psychotic patients 65
or older, and patients with bipolar disorder.
RESULTS: For psychotic patients 45 to 64 years old, que-
tiapine-treated patients remained on treatment for 284
days vs. 261 days for risperidone (P = 0.71), 284 vs. 144
for haloperidol (P < 0.01), and 284 vs. 147 for olanzap-
ine (P < 0.01). Corresponding cost savings for this age
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group were $665.34/year per patient vs. haloperidol,
$95.05 vs risperidone, and $651.08 vs. olanzapine. In the
>65 group, patients persisted with quetiapine for 278
days vs. 201 for risperidone (P = 0.05), 260 vs. 68 for
haloperidol (P < 0.01), and 258 vs. 192 for olanzapine 
(P = 0.16). Cost savings were $912.46/year per patient
for quetiapine vs. haloperidol, $365.93 vs. risperidone,
and $313.66 vs. olanzapine. Annual healthcare costs
were reduced by $4.75 per day (P < 0.01) for each addi-
tional day of persistence. For bipolar patients, the median
persistencies were 225 days for quetiapine compared 
with 98 for haloperidol (P < 0.01), 154 for risperidone
(P < 0.01), and 158 for olanzapine (P < 0.01), yielding
cost savings of $722.63, $403.99 and $438.13, 
respectively.
CONCLUSIONS: Quetiapine had the highest level of
therapy persistence yielding healthcare cost savings com-
pared to other antipsychotics.
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Bipolar disorder is a severe and costly condition that
accounts for approximately $7.6 billion in direct health
care costs in the US. Atypical antipsychotics are increas-
ingly being used for the treatment of Bipolar disorder.
OBJECTIVE: We conducted a retrospective study to
determine whether there are differences in resource 
utilization and cost of care between patients with bipolar
disorder receiving risperidone, olanzapine or quetiapine.
METHODS: In June 2001, 573 persons reported being
diagnosed with bipolar disorder on a self-administered
questionnaire. We compared the utilization of inpatient
and outpatient services as well as mental health-speciﬁc
resources by patients receiving risperidone, olanzapine, or
quetiapine over the previous six months. Drug costs were
not included in the analysis. A regression model was used
to control for use of other drug classes. National cost
multipliers published by the U.S. Census Bureau, 2000,
were used to calculate the cost of care.
RESULTS: Out of the 573 respondents, 108 had sufﬁcient
information on resource utlization for analysis. When
controlling for use of other drug classes, the olanzapine
group (n = 48) had a higher utilization of outpatient 
services (p = 0.008) compared to risperidone (n = 31). The
risperidone group also had lower utilization of inpatient
and outpatient services compared to quetiapine (n = 29),
but the differences were not statistically signiﬁcant. The
cost of care for all services was $8579, $4349, and $5221
for olanzapine, risperidone, and quetiapine, respectively,
while the cost of mental health services was $6186,
$2775, and $4022, respectively.
CONCLUSION: Patients with bipolar disorder receiving
risperidone appear to have lower utilization of healthcare
services and lower costs of care.
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OBJECTIVES: To derive utility values associated with
differing symptoms states of schizophrenia using time
trade-off (TTO) methodology in a community sample.
METHODS: Four clinically signiﬁcant symptom states
were derived from clinical trial data. Scenarios were
grouped into non-responders with extrapyramidal symp-
toms (EPS), non-responders without EPS, responders with
EPS and responders without EPS. A sample of the general
population were given a presentation on the symptoms of
schizophrenia and the side effects of treatment. Respon-
dents then completed the TTO questionnaire in small
groups, trading from a base of 30 years.
RESULTS: 70 participants completed the questionnaire
and traded in a “rational” manner. A mean score of 85%
in a 10-question quiz regarding symptoms of schizophre-
nia and EPS indicated that the presentation had been
understood by participants. The utility scores for each
group were as follows: non-responders with EPS 0.63
(11.0 years traded); non-responders without EPS 0.72
(8.3 years); responders with EPS 0.79 (6.3 years) and
responders without EPS 0.87 (3.8 years). A GEE model
used to analyse these data demonstrated a statistically sig-
niﬁcant effect of health state on mean years traded. Par-
ticipants traded signiﬁcantly more years for the responder
than the non-responder state and, irrespective of respon-
der categorisation, traded signiﬁcantly more years for the
“no EPS” state.
CONCLUSIONS: These results show the ability of a
community sample to value symptoms of schizophrenia
and the side effects of treatment using a time trade-off
methodology. They indicate the value of effective antipsy-
chotic medication that is also associated with a superior
EPS side-effect proﬁle. The implications of these data
when considering cost-effectiveness of antipsychotic 
medication will be discussed.
